Company
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.
Prostate cancer is one of the most common cancers affecting men worldwide. Early detection plays an important role in improving treatment outcomes, but the traditional prostate specific antigen (PSA) blood test has several well known limitations. While PSA screening can identify prostate cancer at an early stage, it may also produce false positive results that lead to unnecessary biopsies. At the same time, it can miss clinically significant cancers that require timely treatment.
A recent study published in the Annals of Internal Medicine examined whether the Stockholm3 blood test offers a more accurate method of prostate cancer screening than the standard PSA test. The findings suggest that Stockholm3 may detect more aggressive prostate cancers while reducing the number of missed cases.
Stockholm3 is an advanced blood based screening test designed to assess a man's risk of clinically significant prostate cancer. Unlike the PSA test, which measures only prostate specific antigen levels, Stockholm3 combines multiple factors into one comprehensive risk assessment.
These factors include:
By analyzing these variables together, Stockholm3 provides a personalized estimate of prostate cancer risk rather than relying on a single biomarker.
PSA testing has been widely used for decades because it is simple and inexpensive. However, elevated PSA levels do not always indicate cancer. Benign prostate enlargement, inflammation, and infections can also increase PSA levels.
As a result, PSA screening can lead to:
Researchers continue to explore more accurate screening methods that balance early detection with fewer unnecessary procedures.
Researchers analyzed data from the STHLM3 MRI prostate cancer screening trial conducted in Sweden between 2018 and 2020.
The study included 12,670 men aged 50 to 74 years. Participants underwent both PSA testing and Stockholm3 testing. Men with abnormal screening results received additional diagnostic evaluation using MRI and prostate biopsy when appropriate.
Researchers also tracked participants through Sweden's National Cancer Register for two years to identify clinically significant prostate cancer that may have been missed during the initial screening.
The study found that Stockholm3 outperformed PSA screening in several important areas.
Stockholm3 detected approximately 90 percent of clinically significant prostate cancers.
Traditional PSA testing detected about 74 percent.
This means Stockholm3 identified substantially more aggressive cancers that may have required treatment.
Missing a clinically significant cancer is one of the biggest concerns in screening.
The researchers found:
This indicates that Stockholm3 missed far fewer cancers than PSA alone.
Despite its improved sensitivity, Stockholm3 maintained a false positive rate that was similar to PSA testing.
This suggests that improved cancer detection did not come at the cost of dramatically increasing unnecessary biopsies.
The goal of prostate cancer screening is not simply to detect more cancer. Instead, it is to identify cancers that are likely to become dangerous while avoiding unnecessary procedures for harmless conditions.
The study suggests that Stockholm3 may achieve a better balance by:
These improvements could help physicians make better recommendations for patients at higher risk.
Although the findings are encouraging, several limitations should be considered.
Only about one quarter of invited men participated in the screening program, which may limit how broadly the results apply.
The follow up period lasted only two years. Longer studies are needed to determine whether improved detection ultimately reduces prostate cancer deaths.
In addition, most participants were of Swedish or European ancestry. More research is needed to confirm similar performance in diverse populations.
Finally, the Stockholm3 test may cost more than standard PSA screening, and future studies will need to evaluate its long term cost effectiveness.
It is still too early to conclude that Stockholm3 should completely replace PSA screening.
However, the study provides strong evidence that combining biomarkers, genetic information, and clinical risk factors can improve prostate cancer detection compared with PSA alone.
As additional research becomes available, Stockholm3 may become an important component of personalized prostate cancer screening strategies, particularly for men at increased risk.
Healthcare providers will continue to evaluate how this test fits into existing screening guidelines and whether it provides sufficient clinical value to justify broader adoption.
Prostate cancer screening continues to evolve as researchers search for more accurate and patient centered approaches.
The latest evidence suggests that Stockholm3 may detect significantly more clinically important prostate cancers than PSA testing while maintaining a similar rate of unnecessary follow up procedures.
Although further long term research is needed, the results represent a promising step toward more precise and effective prostate cancer screening.
Palsdottir T, Micoli C, Eklund M, et al. Stockholm3–Magnetic Resonance Imaging Population Based Prostate Cancer Screening Study: Two Year Follow up. Annals of Internal Medicine. Published June 23, 2026. DOI: 10.7326/ANNALS-25-04753.
This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Individuals should consult a qualified healthcare professional regarding prostate cancer screening, diagnosis, or treatment decisions based on their personal health history.